Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult‐Aged‐Spectrum (SCOPA)
Human Psychopharmacology: Clinical and Experimental · 2025
DOI: 10.1002/hup.70009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, 2025. Verfasst von Levi J M Schuurman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience (FPN), Maastricht University, Maastricht, the Netherland…. Hauptthemen laut MEDLINE: Psychometrics, Psychotropic Drugs, Cognition. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Patient‐reported side‐effect questionnaires contribute to balanced decisions regarding treatment strategy among patients with mental health disorders. However, current side‐effect questionnaires are less suitable for older adults because they often lack age‐specific side effects. Therefore, the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult‐Aged‐Spectrum (SCOPA) was developed to quantify psychotropic side effects across the full adult age spectrum. The aim of this study was to develop and evaluate the reliability and validity of the SCOPA. Procedures Psychometric properties of the SCOPA were assessed in a Dutch patient population ( n = 205, age 18–86 years) and a general population ( n = 281, age 18–87 years). Reliability of the subscales was measured through average inter‐item correlation and Cronbach's alphas. Construct validity was analysed by exploratory factor analysis.
Results
Average inter‐item correlation and Cronbach's alphas of the subscales of the SCOPA were moderate to good. Exploratory factor analyses supported a two‐factor solution, labelled as complaints in somatic and cognitive domains.
Conclusions
This study showed that the SCOPA has promising psychometric qualities and practical capability to evaluate the side‐effect burden of treatment with psychotropic medication across the adult‐aged‐spectrum. However, more research is needed to cross‐validate these results in the field's pursuit of increased patient safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience (FPN), Maastricht University, Maastricht, the Netherlands.
- Clinical Center of Excellence for Older Adults with Personality Disorders, Mondriaan, Mental Health Center, Heerlen, Maastricht, the Netherlands.
- Rotterdam University of Applied Sciences, Rotterdam, the Netherlands.
- Department of Psychiatry and Neuropsychology, Faculty of Health and Life Sciences (FHML), School for Mental Health and Neuroscience (MHeNs), Maastricht University, Maastricht, the Netherlands.
- Vrije Universiteit Brussel (VUB), Personality and Psychopathology Research Group (PEPS), Brussels, Belgium.
ORCID-Profile: Levi J M Schuurman, Julie E M Schulkens
Zitieren
APA
Schuurman, L. J. M., Sobczak, S., Schulkens, J. E. M., Balter, B. P. F., & van Alphen, S. P. J. (2025). Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult‐Aged‐Spectrum (SCOPA). Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.70009
Vancouver
Schuurman LJM, Sobczak S, Schulkens JEM, Balter BPF, van Alphen SPJ. Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult‐Aged‐Spectrum (SCOPA). Human Psychopharmacology: Clinical and Experimental. 2025. doi:10.1002/hup.70009
BibTeX
@article{Schuurman2025,
author = {Schuurman, Levi J M and Sobczak, Sjacko and Schulkens, Julie E M and Balter, Benno P F and van Alphen, Sebastiaan P J},
title = {Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult‐Aged‐Spectrum (SCOPA)},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2025},
doi = {10.1002/hup.70009}
}
EUVIMED